SGLT2 inhibitors, which confer cardiovascular benefits in T2DM patients, can also exert pro-ketogenic effects by mediating a metabolic switch from glucose to lipid utilization. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.